Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CRITICS-II
2023-503248-15-00Phase 2Authorised
- Sponsor
- Netherlands Cancer Institute
- Start
- Jun 2024
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised trial of capecitabine, oxaliplatin, carboplatin, paclitaxel and docetaxel in gastric adenocarcinoma and gastroesophageal junction adenocarcinoma (3 arms), sponsored by Netherlands Cancer Institute. Primary endpoint: Event-free survival at 1 year. Planned start Jun 2024; status: authorised.
02
Drugs
capecitabineoxaliplatincarboplatinpaclitaxeldocetaxel
03
Conditions
gastric adenocarcinomagastroesophageal junction adenocarcinoma
Beyond the preview
Go deeper on 2023-503248-15-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-503248-15-00.